Analysts expect Neurotrope Inc (NASDAQ:NTRP) to report ($0.34) earnings per share (EPS) for the current fiscal quarter, Zacks reports. Zero analysts have provided estimates for Neurotrope’s earnings. Neurotrope posted earnings per share of ($0.47) in the same quarter last year, which indicates a positive year-over-year growth rate of 27.7%. The company is scheduled to report its next quarterly earnings report on Monday, March 9th.
According to Zacks, analysts expect that Neurotrope will report full year earnings of ($1.33) per share for the current financial year. For the next fiscal year, analysts forecast that the business will post earnings of ($1.30) per share. Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side analysts that that provide coverage for Neurotrope.
A number of research firms recently issued reports on NTRP. Maxim Group lowered Neurotrope from a “buy” rating to a “hold” rating in a report on Monday, September 9th. Janney Montgomery Scott lowered Neurotrope from a “buy” rating to a “neutral” rating and lowered their price target for the stock from $13.00 to $1.00 in a report on Wednesday, September 11th. Finally, Zacks Investment Research lowered Neurotrope from a “buy” rating to a “hold” rating in a report on Friday, November 1st.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in NTRP. Virtu Financial LLC purchased a new position in shares of Neurotrope during the third quarter worth about $52,000. Vanguard Group Inc. lifted its position in Neurotrope by 21.7% in the second quarter. Vanguard Group Inc. now owns 266,735 shares of the company’s stock valued at $2,139,000 after purchasing an additional 47,609 shares during the period. BlackRock Inc. lifted its position in Neurotrope by 144.3% in the second quarter. BlackRock Inc. now owns 60,041 shares of the company’s stock valued at $482,000 after purchasing an additional 35,464 shares during the period. Millennium Management LLC acquired a new stake in Neurotrope in the third quarter valued at about $28,000. Finally, NorthRock Partners LLC lifted its position in Neurotrope by 45.5% in the second quarter. NorthRock Partners LLC now owns 104,000 shares of the company’s stock valued at $834,000 after purchasing an additional 32,500 shares during the period. 9.54% of the stock is currently owned by hedge funds and other institutional investors.
Neurotrope, Inc, a biopharmaceutical company, focuses on the development of a product platform for the treatment of Alzheimer's disease. Its lead product candidate is bryostatin, a natural product isolated from a marine invertebrate organism, a bryozoan called Bugula neritina. The company also develops bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X syndrome, multiple sclerosis, and niemann-pick type C diseases.
See Also: Bear Market – How and Why They Occur
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Neurotrope Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurotrope and related companies with MarketBeat.com's FREE daily email newsletter.